Skip to main content

Background


The modulation of hydrogel for controlled therapeutic release maintains an objective to deliver and control the release of therapeutics utilizing a hydrogel delivery system derived from sodium alginate. The therapeutic-infused hydrogel adhesive for controlled release intends to offer treatment for first and second degree burns. The hydrogel alginate complex of the proposed wound dressing rectifies the compromised water barriers which incur from instances of first and second degree burns. As such, the hydrogel alginate complex releases a therapeutic agent into the burn wound while simultaneously hydrating the area, thus averting further injury. The hydrogel wound dressing will be generated by precipitating food-grade sodium alginate in a calcium chloride solution. The reaction will yield spheres of low-density gel encompassed by a thin, gelatinous membrane. Both  high-density and low-density hydrogel layers will be produced, then fashioned between the low-density hydrogel spheres, before the dressing undergoes a freeze-drying process as to produce porous sheets. Pre-existing treatment of first-degree and second-degree burns call for the application of lidocaine anesthetic with aloe vera gel or cream to soothe the infected area. Likewise, an antibiotic ointment may be utilized to further protect the infected area. The hydrogel wound dressing provides for the soothing sensation, typically achieved by pre-existing solutions, with the sterility and protection of pre-existing antibiotic treatments. Consequently, the hydrogel wound dressing functions as comparatively more sterile, efficient treatment of burn wounds.


The video illustrates the production of hydrogel 'beads' and 'worms' utilizing sodium alginate and calcium chloride

Comments

Popular posts from this blog

Week Nine Progress

The progress underwent during week nine of the hydrogel restructuring module entailed rectifying the errors made during the first and second testing rounds conducted during week seven. The results of first and second testing trials revealed egregious errors upon obtaining the results of the spectrophotometry of week eight. The spectrophotometry results delineated a consistent decrease in fluorescent intensity over time. Nonetheless, an ideal graph would illustrate a sustained increase in fluorescent intensity, thereby paralleling an increase in the percentage of therapeutic that is released. The increase in fluorescent intensity which had resulted from the week seven testing may be attributed to the experimental errors which occurred during the construction of hydrogel samples, and are described in full detail in the Week Eight Progress Report.  During week nine, new hydrogel samples were generated in a comparable fashion to the construction of samples during the second phase of t...

Week Eight Progress

During the eighth week of the hydrogel restructuring module, testing trials were conducted to determine the therapeutic release rates of variant hydrogel densities, including sample of: high-density, low-density, intermediate-density, and a layered sample of both high and low densities. The testing of the hydrogel layers was conducted by the injection of the fluorescent signal protein, FITC-BSA, within each sample. The hydrogel samples containing FITC-BSA were constructed at three-six hour intervals, then tested concurrently through the spectrophotometer. The testing phase was completed twice during week eight. During the first testing phase, the employment of tap water in the construction of the samples had produced hydrogel samples that were not uniform in consistency. As such, a second trial was conducted in which pure water was utilized to account for the mistakes of the first testing phase. The second trial proceeded to the spectrophotometer phase of testing. The results of the s...

Week Three Progress

During Week Three, we discussed and determined our therapeutic agent for the hydrogel module. After extensive research and comparison of our options, we decided the best-suited therapeutic would be zinc oxide. This substance fits our design so well because it is hydrophobic and will slowly disperse through the pores in the bottom hydrogel layer. Zinc oxide has been used in past hydrogel models and has been proven to be effective. It is an agent that has been used in ointments and supplements to treat burns and prevent infections. Likewise, the possibility of overdosing on zinc-oxide necessitates a solution for controlled therapeutic release. The predominant delivery system for zinc oxide is through medicinal cream, the delivery through which enables the therapeutic threshold of zinc oxide to be increased to levels of high toxicity. Symptoms of zinc-oxide overdose include: fever, chills, vomiting, mouth irritation, stomach pain, and yellowing of the eyes and skin. Consequently, the phar...